

RESULTS OF NOVEMBER 21, 2017 EXTRAORDINARY MEETING OF SHAREHOLDERS

An extraordinary meeting of the shareholders of Forward Pharma A/S (the "Company") was held on November 21, 2017 at the Company's offices, Østergade 24A, 1, 1100 Copenhagen K, Denmark (the "Shareholders' Meeting"). DKK 703,569 of the Company's share capital and 70,356,900 votes, respectively, were represented at the Shareholders' Meeting. The results of the Shareholders' Meeting were as follows:

- (a) Adoption of proposed amendment of the Company's articles of association (new article 3.3E with pertaining appendix 3 setting out the principles for the adjustments of the terms and conditions governing certain warrants and deferred share awards and compensation of relevant award holders due to the changes in the Company's capital structure resolved on the Company's extraordinary general meeting of August 2, 2017).
- (b) Adoption of the proposed authorisation of the chairman of the extraordinary general meeting to on behalf of the Company apply to the Danish Business Authority for registration of the resolution passed, and in this connection to make any such amendments and supplements to the application and the resolution that may be required as a condition for registration.

Both proposals were adopted by 70,356,900 votes in favour, and with 0 votes against and 0 abstentions, and in the forms proposed by the board of directors.